The purpose of this study is to investigate women who have had a second diagnosis of endometrial cancer and assess any trends in the disease’s presentation or diagnosis. A look back at women who were diagnosed with endometrial cancer between 2014 and 2020. The recurrence rates of diseases were analyzed. The presentation at the time of recurrence was the primary focus of the medical record review. A χ2, Fisher’s exact test, t-test, and Wilcoxon test were used to analyze the connections between variables. Survival was calculated using the Kaplan-Meier product limit method. 

Covariate effects were evaluated using a multiple logistic regression model. In 201 individuals or 11.7%, a recurrence of endometrial cancer was detected. About 120 of the patients (60%) complained of illness. The majority of patients (23.4%; 47/201) reported experiencing pain upon arrival, while only less than 14% (28/201) reported experiencing bleeding. For patients presenting with symptoms, the likelihood of receiving therapy for the recurrent disease was lower (76.7% versus 91.3%, P=0.005). Recurrence was more likely to be found in patients who had been initially diagnosed with an early-stage illness  (66.7% vs 34.5% P=0.001) of endometrioid histology (66.7% vs 36.8%, P=0.003) and who had not had adjuvant therapy (48.2% vs 17.9%, P=0.001) when an asymptomatic pelvic exam was performed. 

Over 1/3rd of patients had their diagnosis established by specialists who weren’t part of the oncology care team. Pain is a typical complaint among women who have experienced a recurrence of their endometrial cancer. Patients showing signs of illness recurrence have a lower chance of receiving treatment for the recurring disease, although this does not seem to affect their overall survival. Given the growing mortality rate of endometrial cancer further effort is needed to establish interdisciplinary surveillance strategies that will enable meaningful treatment of disease recurrence.